In the EMPA‐REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure (SBP and DBP) compared with placebo at week 12 in patients with type 2 diabetes mellitus (T2DM) and hypertension. In a post‐hoc analysis, we assessed the effect of empagliflozin on SBP and DBP using 24‐hour ambulatory BP monitoring in patients categorized as dippers (sleep‐time mean SBP ≤ 90% of awake‐time mean; n = 417) or non‐dippers (sleep‐time mean SBP > 90% of awake‐time mean; n = 350). In dippers, adjusted mean (SE) changes from baseline in mean 24‐hour SBP (mm Hg) at week 12 were −0.2 (0.7) with placebo vs −3.8 (0.6) and −3.9 (0.7) with empagliflozin 10 and 25 mg, respectively (both
P
< .001 vs placebo). In non‐dippers, these changes were 1.0 (0.7) with placebo vs −1.6 (0.7) with empagliflozin 10 mg (
P
= .013 vs placebo) and −3.8 (0.7) with empagliflozin 25 mg (
P
< .001 vs placebo). In both dippers and non‐dippers, SBP and DBP patterns over 24 hours were maintained. There were no clinically relevant changes in heart rate with empagliflozin. In conclusion, empagliflozin significantly reduced mean 24‐hour SBP compared with placebo in dippers and non‐dippers.